Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure-Reference-Cited by-同舟云学术

Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure

Published:2020-08-22 Issue:10 Volume:2 Page:1761-1766
ISSN:2523-8973
Container-title:SN Comprehensive Clinical Medicine
language:en
Short-container-title:SN Compr. Clin. Med.

Author:

Muslim Shahnawaz,Nasrin Nasrin,Alotaibi Faisal Obaid,Prasad Geeta,Singh Shambhu Kumar,Alam Izhar,Mustafa Gulam

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s42399-020-00407-9.pdf

Reference33 articles.

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92:401–2. https://doi.org/10.1002/jmv.25678.

2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coreonavirus: the species and itsviruses-a statement of the Coronavirus Study Group. bioRxiv. 2020. https://doi.org/10.1101/2020.02.07.937862.

3. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. https://doi.org/10.1186/1743-422X-2-69.

4. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71. https://doi.org/10.1038/s41422-020-0282-0.

5. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3. https://doi.org/10.5582/bst.2020.01047.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial;eClinicalMedicine;2024-01

2. An analysis of fatal adverse conditions in temporal association of COVID-19 vaccination to boost the safety of vaccination for COVID-19;The Egyptian Journal of Internal Medicine;2023-02-07

3. A Closer Look at ACE2 Signaling Pathway and Processing during COVID-19 Infection: Identifying Possible Targets;Vaccines;2022-12-21

4. Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions;Herz;2022-11-04

5. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19;Drug Delivery and Translational Research;2022-10-19